046210 — HLB PanaGene Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for HLB PanaGene Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	7,950	16,267	15,601	14,171	12,252
Cost of Revenue
Gross Profit	5,102	10,883	10,625	9,633	8,223
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	4,928	11,118	11,436	12,589	14,091
Operating Profit	3,023	5,149	4,165	1,582	-1,839
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,505	4,916	4,967	2,240	-5,538
Provision for Income Taxes
Net Income After Taxes	3,505	4,916	4,967	2,240	-4,816
Net Income Before Extraordinary Items
Net Income	3,505	4,916	4,967	2,240	-4,816
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,505	4,916	4,967	2,240	-4,816
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-3.85	151	155	68.7	-135
Dividends per Share